Additional clinical trial should be necessary during postmarketing surveillance
Published: 2009-07-06 06:56:00
Updated: 2009-07-06 06:56:00
Drug makers are obligated to conduct the additional clinical trial of a pharmaceutical drug in the period of postmarketing surveillance (PMS), under the newly revised regulation over re-examination of the drug, according to the Korea Food and Drug Administration.
The drug agency said the newly...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
